查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576525

阿茲海默症藥物的市場規模、佔有率、預測和趨勢分析：按藥物（膽鹼酯□抑製劑、NMDA 受體、谷氨酸調節劑）、按應用（疾病進展、症狀管理）- 到2031年的全球預測

Alzheimer's Drugs Market Size, Share, Forecast, & Trends Analysis by Drug (Cholinesterase Inhibitor, NMDA Receptor, Glutamate Regulator) Application (Disease Progression, Symptom Management) - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 | 商品交期: 5-7個工作天內

價格

阿茲海默症藥物市場預計到2031年將達到96.2億美元，2024年至2031年複合年增長率為9.8%。

該報告經過廣泛的二級和一級研究以及對市場情景的深入分析，對主要市場推動因素、阻礙因素、課題和機會進行了分析。該市場的成長是由阿茲海默症全球負擔日益加重、風險因素盛行率增加、研究經費增加、創新技術引進、批准數量增加、臨床試驗和管道產品數量增加等推動的。各種因素。然而，藥物可能產生的副作用和替代療法的使用正在限制市場成長。

此外，新興市場研究活動的增加、意識計劃的提高、公共和私人組織的舉措、聯合藥物療法的使用、生物標記物和成像技術用於診斷和管理等的使用預計將為參與者提供成長機會經營這個市場。然而，阿茲海默症藥物研發成本高、臨床試驗失敗率高、審批流程長且複雜，為市場成長帶來重大課題。

目錄

第一章簡介

第二章研究方法

第 3 章執行摘要

第 4 章市場洞察

  • 摘要
  • 促進因素
    • 阿茲海默症的全球負擔日益加重
    • 危險因子的發生率增加
    • 增加研究經費
    • 引進創新技術
    • 批准數量增加
    • 臨床試驗和管道產品數量增加
  • 阻礙因素
    • 藥物副作用的可能性
    • 使用替代療法
  • 機會
    • 增加新興國家的研究活動
    • 擴大宣傳計劃
    • 公共機構和私人組織的努力
    • 使用藥物合併療法
    • 使用生物標記和影像技術進行診斷和管理
  • 課題
    • 阿茲海默症藥物的研發成本高昂
    • 阿茲海默症藥物臨床試驗失敗率高
    • 阿茲海默症藥物的審批流程漫長而複雜
  • 因素分析
  • 趨勢
  • 藥物分析
  • 價格分析
  • 管道分析
  • 波特五力分析

第五章阿茲海默症藥物市場評估：依藥物類型劃分

  • 摘要
  • 膽鹼酯□抑制劑
    • 多奈□齊
    • 加蘭他敏
    • 卡巴拉汀
  • NMDA 受體拮抗劑
  • 麩胺酸調節劑
  • 複方藥物

第六章阿茲海默症藥物市場評估：依應用分類

  • 摘要
  • 疾病進展
  • 症狀管理
    • 失智症
    • 失眠
    • 其他症狀

第七章阿茲海默症藥物市場評估：按地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 瑞士
    • 比利時
    • 其他歐洲 (RoE)
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 其他亞太地區 (RoAPAC)
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲 (RoLATAM)
  • 中東/非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東/非洲

第 8 章競爭分析

  • 摘要
  • 主要成長策略
  • 競爭基準測試
  • 競爭對手儀表板
    • 行業領導者
    • 市場差異化因素
    • 先鋒公司
    • 新興公司
  • 主要公司的市佔率分析/市場排名（2023 年）

第九章公司簡介（公司概況、財務概況、產品組合、策略發展現況）

  • Biogen
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Eisai Co., Ltd.
  • SUPERNUS PHARMACEUTICALS, INC.
  • H. Lundbeck A/S
  • AC Immune SA
  • Zydus Lifesciences Limited
  • Johnson & Johnson
  • Daiichi Sankyo Company

（註：包含前5名公司的SWOT分析）

第 10 章附錄

Product Code: MRHC - 1041264

Alzheimer's Drugs Market Size, Share, Forecast, & Trends Analysis by Drug (Cholinesterase Inhibitor [Donepezil, Galantamine, Rivastigmine], NMDA Receptor, Glutamate Regulator) Application (Disease Progression, Symptom Management)-Global Forecast to 2031

The Alzheimer's Drugs Market is Projected to Reach $9.62 Billion by 2031 at a CAGR of 9.8% From 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market can be attributed to various factors, such as the increasing burden of Alzheimer's disease globally, rising prevalence of risk factors, increase in research funding, introduction of innovative technologies, increasing number of approvals, and increasing number of clinical trials and pipeline products. However, possible side effects of drugs and the use of substitute treatments are restraining the market growth.

Furthermore, growing research activities in developing countries, an increase in awareness programs, initiatives by public and private organizations, the use of combination drug therapy, and the use of biomarkers and imaging techniques for diagnosis and management are expected to offer growth opportunities to the players operating in this market. However, the high cost of research and development, the high failure rate in clinical trials, and the lengthy and complex regulatory approval process for Alzheimer's drugs are major challenges to the market's growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the Alzheimer's drugs market are Biogen (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eisai Co., Ltd. (Japan), Supernus Pharmaceuticals Inc. (U.S.), H. Lundbeck A/S (Denmark), AC Immune SA (Switzerland), Zydus Lifesciences Limited (India), Johnson & Johnson (U.S.), and Daiichi Sankyo Company (Japan).

Among all the drug types studied in this report, in 2024, the cholinesterase inhibitors segment is expected to account for the largest share of 46.9% of the Alzheimer's drugs market. The cholinesterase inhibitors segment is further divided into donepezil, galantamine, and rivastigmine. The large share of the segment is attributed to the rising prevalence of Alzheimer's disease, the increasing aging population, rising approval for cholinesterase inhibitors, and the increasing effectiveness of drugs. Additionally, donepezil is used to treat all the stages of Alzheimer's disease, that is, early, middle, and late, further increasing the demand for these drugs, thus contributing to the largest share of the segment.

Among all the applications studied in this report, in 2024, the symptom management segment is expected to account for the largest share of the Alzheimer's drugs market. The symptom management segment is further divided into dementia, insomnia, and other symptoms. The large share of the segment is attributed to the availability of a greater number of symptom-management drugs compared to disease progression and increasing focus on symptom management. The focus on symptom management is increasing to slower the disease progression to reduce the cost and healthcare resources associated with it. Additionally, symptom management improves the patient's quality of life, reduces dependency on caregivers, and improves patient safety by addressing the symptoms of dementia, impaired judgment, and confusion symptoms.

An in-depth analysis of the geographical scenario of the global Alzheimer's drugs market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the Alzheimer's drugs market. The largest share of the region is attributed to the increasing prevalence of Alzheimer's disease, rising number of clinical trials for Alzheimer's drugs, increasing funding for the development of Alzheimer's drugs, and increasing awareness programs. Also, supportive government initiatives to reduce the prevalence of Alzheimer's disease are further contributing to the largest share of the segment. For instance, the U.S. Department of Health and Human Services signed a law, namely, the National Alzheimer's Project Act (NAPA). The objective of NAPA is to prevent and effectively treat Alzheimer's disease by 2025.

Scope of the Report:

Alzheimer's Drug Market Assessment-by Drug Type

  • Cholinesterase Inhibitors
    • Donepezil
    • Galantamine
    • Rivastigmine
  • NMDA Receptor Antagonists
  • Glutamate regulators
  • Combination Drugs

Alzheimer's Drug Market Assessment-by Application

  • Disease Progression
  • Symptoms Management
    • Dementia
    • Insomnia
    • Other Symptoms

Note: Other symptoms include loss of spontaneity, depression, hallucination, or paranoia.

Alzheimer's Drug Market Assessment-by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Switzerland
  • Belgium
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific (RoAPAC)
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
  • 2.3. Market Sizing and Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Drivers
    • 4.2.1. Increasing Burden of Alzheimer's Disease Globally
    • 4.2.2. Rising Prevalence of Risk Factors
    • 4.2.3. Increase in Research Funding
    • 4.2.4. Introduction of Innovative Technologies
    • 4.2.5. Increasing Number of Approvals
    • 4.2.6. Increasing Number of Clinical Trials and Pipeline Products
  • 4.3. Restraints
    • 4.3.1. Possible Side Effects of Drugs
    • 4.3.2. Use of Substitute Treatment
  • 4.4. Opportunities
    • 4.4.1. Growing Research Activities in Developing Countries
    • 4.4.2 Increase in Awareness Programs
    • 4.4.3. Initiatives by Public and Private Organizations
    • 4.4.4. Use of Combination Drug Therapy
    • 4.4.5. Use of Biomarkers and Imaging Techniques for Diagnosis and Management
  • 4.5. Challenges
    • 4.5.1. High Cost of Research and Development for Alzheimer's Drugs
    • 4.5.2. High Failure Rate in Clinical Trials for Alzheimer's Drugs
    • 4.5.3. Lengthy and Complex Regulatory Approval Process for Alzheimer's Drugs
  • 4.6. Factor Analysis
  • 4.7. Trends
  • 4.8. Regulatory Analysis
  • 4.9. Pricing Analysis
  • 4.10. Pipeline Analysis
  • 4.11. Porter's Five Force Analysis

5. Alzheimer's Drugs Market Assessment-by Drug Type

  • 5.1. Overview
  • 5.2. Cholinesterase Inhibitors
    • 5.2.1. Donepezil
    • 5.2.2. Galantamine
    • 5.2.3. Rivastigmine
  • 5.3. NMDA receptor antagonists
  • 5.4. Glutamate regulators
  • 5.5. Combination Drugs

6. Alzheimer's Drugs Market Assessment-by Application

  • 6.1. Overview
  • 6.2. Disease Progression
  • 6.3. Symptoms Management
    • 6.3.1. Dementia
    • 6.3.2. Insomnia
    • 6.3.3. Other Symptoms

7. Alzheimer's Drugs Market Assessment-by Geography

  • 7.1. Overview
  • 7.2. North America
    • 7.2.1. U.S.
    • 7.2.2. Canada
  • 7.3. Europe
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Switzerland
    • 7.3.7. Belgium
    • 7.3.8. Rest of Europe (RoE)
  • 7.4. Asia-Pacific
    • 7.4.1. Japan
    • 7.4.2. China
    • 7.4.3. India
    • 7.4.4. South Korea
    • 7.4.5. Rest of Asia-Pacific (RoAPAC)
  • 7.5. Latin America
    • 7.5.1. Brazil
    • 7.5.2. Mexico
    • 7.5.3. Argentina
    • 7.5.4. Rest of Latin America (RoLATAM)
  • 7.6. Middle East & Africa
    • 7.6.1. UAE
    • 7.6.2. Saudi Arabia
    • 7.6.3. South Africa
    • 7.6.4. Rest of Middle East & Africa

8. Competition Analysis

  • 8.1. Overview
  • 8.2. Key Growth Strategies
  • 8.3. Competitive Benchmarking
  • 8.4. Competitive Dashboard
    • 8.4.1. Industry Leaders
    • 8.4.2. Market Differentiators
    • 8.4.3. Vanguards
    • 8.4.4. Emerging Companies
  • 8.5. Market Share Analysis/Market Ranking, by Key Players (2023)

9. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)

  • 9.1. Biogen
  • 9.2. Novartis AG
  • 9.3. F. Hoffmann-La Roche AG
  • 9.4. AbbVie Inc.
  • 9.5. Teva Pharmaceutical Industries Ltd.
  • 9.6. Eisai Co., Ltd.
  • 9.7. SUPERNUS PHARMACEUTICALS, INC.
  • 9.8. H. Lundbeck A/S
  • 9.9. AC Immune SA
  • 9.10. Zydus Lifesciences Limited
  • 9.11. Johnson & Johnson
  • 9.12. Daiichi Sankyo Company

(Note: SWOT analyses of the top 5 companies will be provided.)

10. Appendix

  • 10.1. Available Customization
  • 10.2. Related Reports

LIST OF TABLES

  • Table 1 Global Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 2 Global Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 3 Global Cholinesterase Inhibitors Market, by Country/Region, 2022-2031 (USD Million)
  • Table 4 Global Donepezil Market, by Country/Region, 2022-2031 (USD Million)
  • Table 5 Global Galantamine Market, by Country/Region, 2022-2031 (USD Million)
  • Table 6 Global Rivastigmine Market, by Country/Region, 2022-2031 (USD Million)
  • Table 7 Global NMDA receptor antagonists Market, by Country/Region, 2022-2031 (USD Million)
  • Table 8 Global Glutamate Regulators Market, by Country/Region, 2022-2031 (USD Million)
  • Table 9 Global Combination Drugs Market, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 11 Global Alzheimer's Drugs Market for Disease Progression, by Country/Region, 2022-2031 (USD Million)
  • Table 12 Global Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 13 Global Alzheimer's Drugs Market for Symptoms Management, by Country/Region, 2022-2031 (USD Million)
  • Table 14 Global Alzheimer's Drugs Market for Dementia, by Country/Region, 2022-2031 (USD Million)
  • Table 15 Global Alzheimer's Drugs Market for Insomnia, by Country/Region, 2022-2031 (USD Million)
  • Table 16 Global Alzheimer's Drugs Market for Other Symptoms, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Global Alzheimer's Drugs Market, by Country/Region, 2022-2031 (USD Million)
  • Table 18 North America: Alzheimer's Drugs Market, by Country, 2022-2031 (USD Million)
  • Table 19 North America: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 20 North America: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 21 North America: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 22 North America: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 23 U.S.: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 24 U.S.: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 25 U.S.: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 26 U.S.: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 27 Canada: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 28 Canada: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 29 Canada: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 30 Canada: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 31 Europe: Alzheimer's Drugs Market, by Country/Region, 2022-2031 (USD Million)
  • Table 32 Europe: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 33 Europe: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 34 Europe: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 35 Europe: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 36 Germany: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 37 Germany: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 38 Germany: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 39 Germany: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 40 France: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 41 France: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 42 France: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 43 France: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 44 U.K.: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 45 U.K.: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 46 U.K.: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 47 U.K.: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 48 Italy: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 49 Italy: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 50 Italy: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 51 Italy: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 52 Spain: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 53 Spain: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 54 Spain: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 55 Spain: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 56 Switzerland: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 57 Switzerland: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 58 Switzerland: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 59 Switzerland: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 60 Belgium: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 61 Belgium: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 62 Belgium: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 63 Belgium: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 64 Rest of Europe: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 65 Rest of Europe: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 66 Rest of Europe: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 67 Rest of Europe: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 68 Asia-Pacific: Alzheimer's Drugs Market, by Country/Region, 2022-2031 (USD Million)
  • Table 69 Asia-Pacific: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 70 Asia-Pacific: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 71 Asia-Pacific: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 72 Asia-Pacific: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 73 China: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 74 China: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 75 China: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 76 China: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 77 Japan: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 78 Japan: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 79 Japan: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 80 Japan: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 81 India: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 82 India: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 83 India: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 84 India: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 85 South Korea: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 86 South Korea: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 87 South Korea: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 88 South Korea: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 89 Rest of Asia-Pacific: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 90 Rest of Asia-Pacific: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 91 Rest of Asia-Pacific: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 92 Rest of Asia-Pacific: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 93 Latin America: Alzheimer's Drugs Market, by Country/Region, 2022-2031 (USD Million)
  • Table 94 Latin America: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 95 Latin America: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 96 Latin America: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 97 Latin America: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 98 Brazil: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 99 Brazil: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 100 Brazil: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 101 Brazil: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 102 Mexico: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 103 Mexico: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 104 Mexico: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 105 Mexico: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 106 Argentina: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 107 Argentina: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 108 Argentina: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 109 Argentina: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 110 Rest of Latin America: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 111 Rest of Latin America: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 112 Rest of Latin America: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 113 Rest of Latin America: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 114 Middle East & Africa: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 115 Middle East & Africa: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 116 Middle East & Africa: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 117 Middle East & Africa: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 118 UAE: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 119 UAE: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 120 UAE: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 121 UAE: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 122 Saudi Arabia: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 123 Saudi Arabia: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 124 Saudi Arabia: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 125 Saudi Arabia: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 126 South Africa: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 127 South Africa: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 128 South Africa: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 129 South Africa: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 130 Rest of Middle East & Africa: Alzheimer's Drugs Market, by Drug Type, 2022-2031 (USD Million)
  • Table 131 Rest of Middle East & Africa: Cholinesterase Inhibitors Market, by Type, 2022-2031 (USD Million)
  • Table 132 Rest of Middle East & Africa: Alzheimer's Drugs Market, by Application, 2022-2031 (USD Million)
  • Table 133 Rest of Middle East & Africa: Alzheimer's Drugs Market for Symptoms Management, by Type, 2022-2031 (USD Million)
  • Table 134 Recent Developments, by Company, 2020-2024

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Key Secondary Sources
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
  • Figure 6 Market Size Estimation
  • Figure 7 Global Alzheimer's Drugs Market, by Drug Type, 2024 VS. 2031 (USD Million)
  • Figure 8 Global Alzheimer's Drugs Market, by Application, 2024 VS. 2031 (USD Million)
  • Figure 9 Global Alzheimer's Drugs Market, by Geography
  • Figure 10 Global Alzheimer's Drugs Market, by Drug Type, 2024 VS. 2031 (USD Million)
  • Figure 11 Global Alzheimer's Drugs Market, by Application, 2024 VS. 2031 (USD Million)
  • Figure 12 Global Alzheimer's Drugs Market, by Geography, 2024 VS. 2031 (USD Million)
  • Figure 13 North America: Alzheimer's Drugs Market Snapshot
  • Figure 14 Europe: Alzheimer's Drugs Market Snapshot
  • Figure 15 Asia-Pacific: Alzheimer's Drugs Market Snapshot
  • Figure 16 Latin America: Alzheimer's Drugs Market Snapshot
  • Figure 17 Middle East & Africa: Alzheimer's Drugs Market Snapshot
  • Figure 18 Key Growth Strategies Adopted by Leading Players, 2020-2024
  • Figure 19 Global Alzheimer's Drugs Market: Competitive Benchmarking, by Drug Type
  • Figure 20 Global Alzheimer's Drugs Market: Competitive Benchmarking, by Geography
  • Figure 21 Global Alzheimer's Drugs Market: Competitive Dashboard
  • Figure 22 Global Alzheimer's Drugs Market: Market Share Analysis/Market Ranking, By Key Players (2024)
  • Figure 23 Biogen: Financial Snapshot (2024)
  • Figure 24 Novartis AG: Financial Snapshot (2024)
  • Figure 25 F. Hoffmann-La Roche AG: Financial Snapshot (2024)
  • Figure 26 AbbVie Inc.: Financial Snapshot (2024)
  • Figure 27 Teva Pharmaceutical Industries Ltd.: Financial Snapshot (2024)
  • Figure 28 Eisai Co., Ltd.: Financial Snapshot (2024)
  • Figure 29 SUPERNUS PHARMACEUTICALS, INC.: Financial Snapshot (2024)
  • Figure 30 H. Lundbeck A/S: Financial Snapshot (2024)
  • Figure 31 AC Immune SA: Financial Snapshot (2024)
  • Figure 32 Zydus Lifesciences Limited: Financial Snapshot (2024)
  • Figure 33 Johnson & Johnson: Financial Snapshot (2024)
  • Figure 34 Daiichi Sankyo Company: Financial Snapshot (2024)